PB 32 of 2024 National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024 I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination. Dated 27 March 2024 Nikolai Tsyganov Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health and Aged Care Contents 1 Name 2 Commencement 3 Authority 4 Schedules Schedule 1—Amendments commencing immediately after the commencement of Schedule 3 to the National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023 National Health (Minimum Stockholding) Determination 2023 Schedule 2—Amendments commencing 1 April 2024 National Health (Minimum Stockholding) Determination 2023 1 Name (1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024. (2) This instrument may also be cited as PB 32 of 2024. 2 Commencement (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms. Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table 1 April 2024. 1 April 2024 2. Schedule 1 Immediately after the commencement of Schedule 3 to the National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023. 1 April 2024 3. Schedule 2 1 April 2024. 1 April 2024 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument. 3 Authority This instrument is made under subsection 99AEKC(2) of the National Health Act 1953. 4 Schedules Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms. Schedule 1—Amendments commencing immediately after the commencement of Schedule 3 to the National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023 National Health (Minimum Stockholding) Determination 2023 1 Schedule 1 (table) Omit: Pregabalin Capsule 150 mg Oral Pregabalin Lupin 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together 2 Schedule 1 (table) Omit: Pregabalin Capsule 75 mg Oral Pregabalin Lupin 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together Schedule 2—Amendments commencing 1 April 2024 National Health (Minimum Stockholding) Determination 2023 1 Schedule 1 (table) Before: Aripiprazole Tablet 10 mg Oral APO‑Aripiprazole 3 months stock by reference to usual demand insert: Anastrozole Tablet 1 mg Oral Arimidex between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand 2 Schedule 1 (table) After: Bosentan Tablet 125 mg (as monohydrate) Oral Bosentan Cipla between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand insert: Bosentan Tablet 125 mg (as monohydrate) Oral Tracleer between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand Bosentan Tablet 62.5 mg (as monohydrate) Oral Tracleer between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand 3 Schedule 1 (table) After: Calcium Tablet, chewable, 500 mg (as carbonate) Oral Cal‑500 after 30 November 2023—6 months stock by reference to usual PBS demand insert: Candesartan Tablet containing candesartan cilexetil 16 mg Oral NOUMED CANDESARTAN between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand Candesartan Tablet containing candesartan cilexetil 32 mg Oral NOUMED CANDESARTAN between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand Candesartan Tablet containing candesartan cilexetil 4 mg Oral NOUMED CANDESARTAN between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand Candesartan Tablet containing candesartan cilexetil 8 mg Oral NOUMED CANDESARTAN between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand 4 Schedule 1 (table) After: Clarithromycin Powder for oral liquid 250 mg per 5 mL, 50 mL Oral Klacid 4 months stock by reference to usual PBS demand insert: Clindamycin Capsule 150 mg (as hydrochloride) Oral Clindamycin BNM between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand 5 Schedule 1 (table) Omit: Diclofenac Tablet (enteric coated) containing diclofenac sodium 50 mg Oral Fenac between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand 6 Schedule 1 (table) Omit: Domperidone Tablet 10 mg Oral Motilium between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand 7 Schedule 1 (table) Omit: Folinic acid Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL Injection Leucovorin Calcium (Pfizer Australia Pty Ltd) between 1 March 2024 and 31 July 2024—0 months stock by reference to usual demand 8 Schedule 1 (table) Omit: Glimepiride Tablet 1 mg Oral Aylide 1 between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand Glimepiride Tablet 2 mg Oral Aylide 2 between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand Glimepiride Tablet 3 mg Oral Aylide 3 between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand Glimepiride Tablet 4 mg Oral Aylide 4 between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand 9 Schedule 1 (table) Omit: Hydralazine Tablet containing hydralazine hydrochloride 25 mg Oral Alphapress 25 between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand 10 Schedule 1 (table) Omit: Macrogol 3350 Powder for oral solution 510 g Oral OsmoLax between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand 11 Schedule 1 (table) After: Methoxyflurane Liquid for inhalation 999 mg per g, 3 ml (with inhaler) Inhalation by mouth Penthrox 6 months stock by reference to usual PBS demand insert: Methylprednisolone Injection containing methylprednisolone acetate 40 mg in 1 mL Injection Depo-Nisolone between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand 12 Schedule 1 (table) Omit: Methylprednisolone Powder for injection 40 mg (as sodium succinate) Injection Methylpred between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand 13 Schedule 1 (table) After: Mycophenolic acid Tablet containing mycophenolate mofetil 500 mg Oral CellCept between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand insert: Mycophenolic acid Tablet containing mycophenolate mofetil 500 mg Oral Noumed Mycophenolate between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand 14 Schedule 1 (table) Omit: Oxybutynin Tablet containing oxybutynin hydrochloride 5 mg Oral Ditropan between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand 15 Schedule 1 (table) Before: Pregabalin Capsule 150 mg Oral LYPRALIN between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand insert: Pioglitazone Tablet 30 mg (as hydrochloride) Oral NOUMED PIOGLITAZONE between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand Pioglitazone Tablet 30 mg (as hydrochloride) Oral Pioglitazone Sandoz between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand Pioglitazone Tablet 45 mg (as hydrochloride) Oral NOUMED PIOGLITAZONE between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand Pioglitazone Tablet 45 mg (as hydrochloride) Oral Pioglitazone Sandoz between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand 16 Schedule 1 (table) Omit: Polyethylene glycol 400 with propylene glycol Eye drops 4 mg‑3 mg per mL, 15 mL Application to the Eye Systane between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand 17 Schedule 1 (table) Omit: Pregabalin Capsule 25 mg Oral Pregabalin Lupin 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together 18 Schedule 1 (table) Omit: Pregabalin Capsule 300 mg Oral Pregabalin Lupin 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together 19 Schedule 1 (table) Omit: Prochlorperazine Tablet containing prochlorperazine maleate 5 mg Oral Stemzine between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand 20 Schedule 1 (table) After: Ramipril with felodipine Tablet 2.5 mg‑2.5 mg (modified release) Oral Triasyn 2.5/2.5 4 months stock by reference to usual PBS demand insert: Riluzole Oral suspension 50 mg per 10 mL, 300 mL Oral Teglutik between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand 21 Schedule 1 (table) Omit: Risperidone Tablet 1 mg Oral Risperidone generichealth between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand Risperidone Tablet 2 mg Oral Risperidone generichealth between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand 22 Schedule 1 (table) Omit: Risperidone Tablet 3 mg Oral Risperidone generichealth between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand 23 Schedule 1 (table) After: Risperidone Tablet 4 mg Oral Risperidone generichealth between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand insert: Rosuvastatin Tablet 10 mg (as calcium) Oral Noumed Rosuvastatin between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand Rosuvastatin Tablet 20 mg (as calcium) Oral Noumed Rosuvastatin between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand Rosuvastatin Tablet 40 mg (as calcium) Oral Noumed Rosuvastatin between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand Rosuvastatin Tablet 5 mg (as calcium) Oral Noumed Rosuvastatin between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand 24 Schedule 1 (table) Omit: Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate Enemas 3.125 g‑450 mg‑45 mg in 5 mL, 12 Rectal Micolette between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand 25 Schedule 1 (table) After: Thiamine Tablet containing thiamine hydrochloride 100 mg Oral Betavit 4 months stock by reference to usual PBS demand insert: Tobramycin Injection 80 mg (as sulfate) in 2 mL (without preservative) Injection Pfizer Australia Pty Ltd between 1 April 2024 and 30 September 2024—4 months stock by reference to usual demand 26 Schedule 1 (table) After: Topiramate Tablet 100 mg Oral APO‑Topiramate 3 months stock by reference to usual demand insert: Topiramate Tablet 100 mg Oral NOUMED TOPIRAMATE between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand 27 Schedule 1 (table) After: Topiramate Tablet 200 mg Oral APO‑Topiramate 3 months stock by reference to usual demand insert: Topiramate Tablet 200 mg Oral NOUMED TOPIRAMATE between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand 28 Schedule 1 (table) After: Topiramate Tablet 25 mg Oral APO‑Topiramate 3 months stock by reference to usual demand insert: Topiramate Tablet 25 mg Oral NOUMED TOPIRAMATE between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand 29 Schedule 1 (table) After: Topiramate Tablet 50 mg Oral APO‑Topiramate 3 months stock by reference to usual demand insert: Topiramate Tablet 50 mg Oral NOUMED TOPIRAMATE between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand 30 Schedule 1 (table) Omit: Tropisetron I.V. injection 5 mg (as hydrochloride) in 5 mL Injection Tropisetron-AFT between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand 31 Schedule 1 (table) After: Trimethoprim Tablet 300 mg Oral Trimethoprim Viatris after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together insert: Valaciclovir Tablet 500 mg (as hydrochloride) Oral NOUMED VALACICLOVIR between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand 32 Schedule 1 (table) Omit: Vinorelbine Solution for I.V. infusion 10 mg (as tartrate) in 1 mL Injection Navelbine between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand 33 Schedule 1 (table) Omit: Voriconazole Tablet 200 mg Oral Vfend between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand